New approaches to cancer therapies

Journal of Pathology

Volumn 187, Issue 1, 1999, Pages 138-146

  Fåhraeus, Robin ^a   Fischer, Peter ^b   Krausz, Eberhard ^b   Lane, David P ^a,b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b CYCLACEL LTD   (United Kingdom)

Author keywords

Angiogenesis; Chemotherapeutic; Gene therapy; p16(INK4a); p21(ras); p53; Target discovery

Indexed keywords

GENE PRODUCT; PROTEIN P16; PROTEIN P53;

ANGIOGENESIS; CANCER THERAPY; GENE THERAPY; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0032961229     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:1<138::AID-PATH252>3.0.CO;2-M     Document Type: Review

References (90)

1. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature 1993; 366; 704-707.
2. Weinberg R. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
3. 1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
4. INK4b is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257-261.
5. Hirai H, Roussel M, Kato J, Ashmun R, Sherr C. Novel INK4 proteins p19 and p18, are specific inhibitors of cyclin D-dependent kinases cdk4 and cdk6. Mol Cell Biol 1995; 15: 2672-2681.
6. INK4a. Mol Cell Biol 1995; 15: 2682-2688.
7. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancers. Adv Cancer Res 1996; 68: 67-108.
8. Serrano M, Lin A, McCurrach M, Beach D, Lowe S. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
9. McConnel B, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human fibroblasts. Curr Biol 1998; 8: 351-354.
10. INK4a/MTSI) and cdk4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996; 13: 1065-1072.
11. Reed JA, Loganzo F, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumour suppressor gene in melanocytic lesions correlates with invasive stages of tumour progression. Cancer Res 1995; 55: 2713-2718.
12. 16INK4a transcript. Cancer Res 1995; 55: 2995-3000.
13. ARF, interacts with MDM2 and neutralizes MDM2s inhibition of p53. Cell 1998; 92: 713-723.
14. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilises p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumour suppression pathways. Cell 1998; 92: 725-734.
15. ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 1998; 91: 1016-1020.
16. INK4 function. Nature Genet 1995; 10: 114-116.
17. INK4a. Curr Biol 1996; 6: 84-91.
18. Fåhraeus R, Lain S, Ball K, Lane DP. Characterisation of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene 1998; 16: 587-596.
19. Derossi D, Joliol AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-10450.
20. Fåhraeus R, Lane DP. Inhibition of G1 associated cyclin-dependent kinases results in loss of spreading on vitronectin and dissociation of the αvβ3 integrin from focal adhesion contacts (submitted).
21. Chimala SK, Fueyo J, Gomez-Manzano C, et al. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 1997; 15: 2049-2057.
22. Marshall JF, Hart I. The role of αv-integrins in tumour progression and metastasis. Cancer Biol 1996; 7: 129-138.
23. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264: 569-571.
24. WAF1. Curr Biol 1997; 7: 81-87.
25. Selivanova G, Iotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 1997; 3: 632-638.
26. Hupp T, Sparks A, Lane D. Small peptides activate the latent sequence-specific DNA-binding function of p53. Cell 1995; 83: 237-245.
27. Bottger V, Bottger A, Howard S, et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996; 13: 2141-2147.
28. Bottger A, Bottger V, Sparks A, Liu W-L, Howard S, Lane D. Design of a synthetic Mdm2-binding protein that activates the p53 response in vivo. Curr Biol 1997; 7: 860-869.
29. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
30. Clark GJ, Der CJ. ras protooncogene activation in human malignancy. In: Garrett CT, Sell S, eds. Cellular Cancer Markers. Totowa, NJ: Humana; 17-52.
31. Downward J. Ras signalling and apoptosis. Curr Opin Gen Dev 1998; 8: 49-54.
32. Lloyd AC. Ras versus cyclin-dependent kinase inhibitors. Curr Opin Gen Dev 1998; 8: 43-48.
33. Prendergast GC, Gibbs JB. Regulatory interactions in Ras signal transduction: new targets for anti-cancer intervention?' BioEssays 1994; 16: 187-191.
34. Spaargaren M, Bischoff JR, McCormick F. Signal transduction by Ras-like GTPases: a potential target for anticancer drugs. Gene Exp 1995; 4: 345-356.
35. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997; 37: 143-166.
36. Lowy DR, Willumsen BM. Function and regulation of Ras. Annu Rev Biochem 1993; 62: 851-891.
37. Casey P, Seabra M. Protein prenyltransferases. J Biol Chem 1996; 271: 5289-5292.
38. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260: 1934-1937.
39. Yoshimatsu K, Nagasu T. Anti-tumor activity of farnesyl transferase inhibitor. Gan To Kagaku Ryoho 1997; 24: 145-155.
40. Vogt A, Qian Y, Blaskovich M, Possum R, Hamilton A, Sebti S. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J Biol Chem 1995; 270: 660-664.
41. Njoroge F, Vibulbhan B, Pinto P, et al. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity. J Med Chem 1998; 41: 1561-1567.
42. Hara M, Akasaka K, Akinaga S, et al. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 1993; 90: 2281-2285.
43. Cassidy PB, Poulter CD. Transition state analogs for protein farnesyltransferase. J Am Chem Soc 1996; 118: 8761-8762.
44. Sebti S, Hamilton A. Inhibitors of prenyl transferases. Curr Opin Oncol 1997; 9: 557-561.
45. WAF1/CIP1/SDI1 in a p53-independent manner. J Biol Chem 1997; 272: 27224-27229.
46. Pahan K, Sheikh F, Namboodiri A, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100: 2671-2679.
47. Lavelle F. Farnesyl transferase inhibitors in oncology: from basic research to pharmaceutical research. C R Soc Biol 1997; 191: 211-219.
48. Stacey DW, Feig LA, Gibbs JB. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol Cell Biol 1991; 11: 4053-4064.
49. Moasser MM, Sepp-Lorenzino L, Kohl NL, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998; 95: 1369-1374.
50. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
51. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Canter Inst 1989; 82: 4-6.
52. Folkman J, Klagsburn M. Angiogenic factors. Science 1987; 235: 442-447.
53. Namiki A, Brogi E, Kearney M, et al. Hypoxia induces vascular endothelial growth factor in cultured endotlielial cells. J Biol Chem 1995; 270: 31189-31195.
54. Kim K, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
55. Fong T, McMahon G, Kim Y, et al. Small molecule inhibitors of Flk-1 suppress subcutaneous growth of multiple tumour types, inhibit angiogenesis and produce attenuation of metastasis. Proc Am Assoc Cancer Res 1997; 38: 1789.
56. Strawn L, McMahon G, App H, et al. Flk-1 as target for tumour growth inhibition. Cancer Res 1996; 56: 3540-3545.
57. Mazure N, Chen E, Yeh P, Laderoute K, Giaccia A. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996; 56: 3436-3440.
58. O'Reilly M, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
59. O'Reilly M, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997; 88: 227-285.
60. Gately S, Twardowski P, Stack M, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor angiostatin. Cancer Res 1996; 56: 4887-4990.
61. Kerbel RS. Inhibition of tumour angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991; 13: 31-36.
62. Boehm T, Folkman J, Browder T, O'Reilley M. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
63. Wojtowicz-Praga S, Dickson R, Hawkins M. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75.
64. Huang X, Molema G, King S, Watkins L, Edgington T, Thorpe P. Tumour infarcation in mice by antibody-directed targeting of tissue factor to tumour vasculature. Science 1997; 275: 547-550.
65. Favrot M, Coll J-L, Louis N, Negoescu A. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes. Gene Ther 1998; 5: 728-739.
66. Roth J, Cristiano R. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Int 1997; 89: 21-39.
67. Hamel W, Magnelli L, Chiarugi V, Israel M. HSV-TK/ganciclovir-mediated apoptotic death by bystander cells. Center Res 1996; 56: 2696-2702.
68. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998; 58: 2288-2292.
69. Wyllie A. The biology of death in tumours. Anticancer Res 1985; 5: 131-136.
70. Kerr J, Searle J. A suggested explanation tor the paradoxically slow growth rate of basal-cell carcinomas that contains numerous mitotic figures. J Pathol 1972; 107: 41-44.
71. Schatten W. An experimental study of necrosis in tumours. Cancer Res 1962; 22: 286-292.
72. Sarraf C, Bowen I. Proportions of mitotic and apoptotic cells in a range of untreated experimental tumours. Cell Tissue Kinet 1988; 21: 45-49.
73. Verma IM, Somia N. Gene therapy promises, problems and prospects. Nature 1997; 389: 239-242.
74. Weichselbaum RR, Kufe D. Gene therapy of cancer. Lancet 1997; 349 (Suppl II): 10-12.
75. Yang E, Korsmeyer S. Molecular thanatopsis: a discourse on the bcl2 family and cell death. Blood 1996; 88: 386-401.
76. Brambilla E, Negoescu A, Gazzeeri S, et al. Apoptosis-related factors p53, bcl2 and bax in neuroendocrine tumours. Am J Pathol 1996; 149: 1941-1942.
77. Kernohan N, Cox L. Regulation of bcl2 and its related proteins: immunocytochemical challenges and therapeutic implications. J Pathol 1996; 179: 1-3.
78. Miyashita T, Harigai M, Hanada M, Reed J. Identification of a p53 dependent negative response element in the bcl2 gene. Cancer Res 1994; 54: 3131-3135.
79. Miyashita T, Reed J. Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
80. Cher X, Ko L, Jayaraman L, Prives C. p53 levels, functional domains and DNA damage determine the extent of the apoptotic response of tumour cells. Genes Dev 1996; 56: 694-699.
81. Lassus P, Frelin M, Piette J, Hubner U. Anti-apoptotic activity of low levels of wild-type p53. EMBO J 1996; 15: 4566-4573.
82. Lowe S, Schmitt E, Smith S, Osborne B, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-848.
83. Lowe S, Ruley H, Jacks T, Housman D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
84. Yang B, Eshelman J, Berger N, Markowitz S. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996; 2: 1647-1657.
85. Fujiwara T, Grimm E, Mukhopadhyay T, Zhang W, Owen-Schaub L, Roth J. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of wild type p53 gene. Cancer Res 1994; 54: 2287-2291.
86. Wahl A, Donaldson K, Fairchild C, et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Mat 1996; 2: 72-79.
87. Brough D, Lizonova A, Hsu C, Kulesa V, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early region E1 and E4. J Virol 1996; 70: 6497-6501.
88. Bischoff J, Kim D, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient cells. Science 1996; 274: 373-376.
89. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review. Oncol Res 1997; 9: 313-325.
90. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nature Med 1997; 3: 515-520.